Prognostic Significance of ABO Blood Type in Patients with Advanced Pancreatic Cancer Treated with Nab-Paclitaxel Plus Gemcitabine.

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Pancreas Pub Date : 2025-05-22 DOI:10.1097/MPA.0000000000002515

Kiyotsugu Iede, Terumasa Yamada, Hirotoshi Takayama, Tomo Ishida, Yukako Mokutani, Shinsuke Nakashima, Tsukasa Tanida, Jin Matsuyama, Ken Nakata, Shusei Tominaga

{"title":"Prognostic Significance of ABO Blood Type in Patients with Advanced Pancreatic Cancer Treated with Nab-Paclitaxel Plus Gemcitabine.","authors":"Kiyotsugu Iede, Terumasa Yamada, Hirotoshi Takayama, Tomo Ishida, Yukako Mokutani, Shinsuke Nakashima, Tsukasa Tanida, Jin Matsuyama, Ken Nakata, Shusei Tominaga","doi":"10.1097/MPA.0000000000002515","DOIUrl":null,"url":null,"abstract":"Objectives: The prognostic significance of the ABO blood type in patients with advanced pancreatic cancer (APC) receiving nab-paclitaxel plus gemcitabine (AG) remains unknown. Therefore, we investigated the prognostic significance of the ABO blood type in patients with APC receiving AG.Methods: From January 2015 to May 2023, 90 patients with APC received AG as first-line chemotherapy at Higashiosaka City Medical Center. We analyzed overall survival (OS) based on the ABO blood type using the Kaplan-Meier method and log-rank test, and we retrospectively compared patient characteristics between those with the blood type associated with the worst OS and those with other blood types. Prognostic factors were assessed using Cox regression.Results: The median OS in the B blood type group was significantly shorter (5.0 months) than that in the non-B blood type group (9.6 months, P=0.012). Patients in the B blood type group had a significantly higher prevalence of sarcopenia than those in the non-B blood type group (P=0.011). However, the AG treatment response, progression-free survival during AG, and residual survival with subsequent anti-cancer treatment after AG did not significantly differ between the two groups. The multivariate analysis revealed that the B blood type was an independent unfavorable prognostic factor of OS.Conclusions: Patients with the B blood type had a markedly poorer prognosis and a higher prevalence of sarcopenia. Patients who have APC with the B blood type may require additional supportive treatment for sarcopenia.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPA.0000000000002515","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The prognostic significance of the ABO blood type in patients with advanced pancreatic cancer (APC) receiving nab-paclitaxel plus gemcitabine (AG) remains unknown. Therefore, we investigated the prognostic significance of the ABO blood type in patients with APC receiving AG.

Methods: From January 2015 to May 2023, 90 patients with APC received AG as first-line chemotherapy at Higashiosaka City Medical Center. We analyzed overall survival (OS) based on the ABO blood type using the Kaplan-Meier method and log-rank test, and we retrospectively compared patient characteristics between those with the blood type associated with the worst OS and those with other blood types. Prognostic factors were assessed using Cox regression.

Results: The median OS in the B blood type group was significantly shorter (5.0 months) than that in the non-B blood type group (9.6 months, P=0.012). Patients in the B blood type group had a significantly higher prevalence of sarcopenia than those in the non-B blood type group (P=0.011). However, the AG treatment response, progression-free survival during AG, and residual survival with subsequent anti-cancer treatment after AG did not significantly differ between the two groups. The multivariate analysis revealed that the B blood type was an independent unfavorable prognostic factor of OS.

Conclusions: Patients with the B blood type had a markedly poorer prognosis and a higher prevalence of sarcopenia. Patients who have APC with the B blood type may require additional supportive treatment for sarcopenia.

查看原文本刊更多论文

nab -紫杉醇联合吉西他滨治疗晚期胰腺癌患者ABO血型的预后意义

目的：ABO血型对晚期胰腺癌（APC）患者接受nab-紫杉醇联合吉西他滨（AG）治疗的预后意义尚不清楚。因此，我们研究了ABO血型对APC患者接受抗原治疗的预后意义。方法：2015年1月至2023年5月，90例APC患者在东大阪市医疗中心接受AG作为一线化疗。我们使用Kaplan-Meier方法和log-rank检验分析了基于ABO血型的总生存期（OS），并回顾性比较了与最差OS相关的血型和其他血型的患者特征。采用Cox回归评估预后因素。结果：B血型组患者的中位生存期（5.0个月）明显短于非B血型组患者（9.6个月，P=0.012）。B型血患者的肌少症患病率明显高于非B型血患者（P=0.011）。然而，AG治疗反应、AG期间的无进展生存期和AG后后续抗癌治疗的剩余生存期在两组之间没有显著差异。多因素分析显示，B血型是OS的独立不利预后因素。结论：B型血患者预后明显较差，骨骼肌减少症患病率较高。患有APC的B型患者可能需要额外的支持治疗肌肉减少症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pancreas 医学-胃肠肝病学

CiteScore

4.70

自引率

3.40%

发文量

289

审稿时长

1 months

期刊介绍： Pancreas provides a central forum for communication of original works involving both basic and clinical research on the exocrine and endocrine pancreas and their interrelationships and consequences in disease states. This multidisciplinary, international journal covers the whole spectrum of basic sciences, etiology, prevention, pathophysiology, diagnosis, and surgical and medical management of pancreatic diseases, including cancer.